This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): BAY 59-7939, BAY59-7939, JNJ-39039039, rivaroxaban
Description: Xarelto is an oral anticoagulant under development by Bayer. Xarelto has been shown to inhibit free Factor Xa and prothrombinase activity. In this way, Xarelto prevents thrombin generation in the coagulation pathway.
Deal Structure: In October 2005, Bayer and Johnson & Johnson announced an agreement to jointly develop and market Xarelto for the prevention and treatment of thrombosis. According to the terms of the agreement, J&J will share the global development costs and will make an up front payment along with payments based on achieving certain development milestones in the range of $290 million. Following the launch in the U.S., J&J will pay royalties of up to 30 percent, depending on sales thresholds.
In the U.S., J&J will receive exclusive marketing rights for the cardiology, primary care and hospital specialty markets. Bayer will retain an option to co-promote Xarelto in the hospital and specialty markets through its Specialty Pharmaceutical unit in the U.S. Bayer will also retain sole marketing rights for the compound in countries outside the United States.
In February 2012, Bayer and Almirall announced an agreement to co-promote rivaroxaban (Xarelto) in Spain. Terms of the agreement were not reported.
Partners: Bayer AG
Additional information available to subscribers only: